1. physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. 2. severe liver disease (e.g. child pugh score ≥ c, ast\>5 times upper limit) 3. pregnant or breastfeeding, or positive pregnancy test in a predose examination 4. patients with known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis 5. will be transferred to another hospital which is not the study site within 72 hours. 6. receipt of any experimental treatment for covid-19 within the 30 days prior to the time of the screening evaluation.

1. physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. 2. severe liver disease (e.g. child pugh score ≥ c, ast\>5 times upper limit) 3. pregnant or breastfeeding, or positive pregnancy test in a predose examination 4. patients with known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis 5. will be transferred to another hospital which is not the study site within 72 hours. 6. receipt of any experimental treatment for covid-19 within the 30 days prior to the time of the screening evaluation.

physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. severe liver disease (e.g. child pugh score ≥ c, ast>5 times upper limit) pregnant or breastfeeding, or positive pregnancy test in a predose examination patients with known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis will be transferred to another hospital which is not the study site within 72 hours. receipt of any experimental treatment for covid-19 within the 30 days prior to the time of the screening evaluation.

physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. severe liver disease (e.g. child pugh score ≥ c, ast>5 times upper limit) pregnant or breastfeeding, or positive pregnancy test in a predose examination patients with known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis will be transferred to another hospital which is not the study site within 72 hours. receipt of any experimental treatment for covid-19 within the 30 days prior to the time of the screening evaluation.

1. physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. 2. severe liver disease (e.g. child pugh score ≥ c, ast>5 times upper limit) 3. pregnant or breastfeeding, or positive pregnancy test in a predose examination 4. patients with known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis 5. will be transferred to another hospital which is not the study site within 72 hours. 6. receipt of any experimental treatment for covid-19 within the 30 days prior to the time of the screening evaluation.

1. physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. 2. severe liver disease (e.g. child pugh score ≥ c, ast>5 times upper limit) 3. pregnant or breastfeeding, or positive pregnancy test in a predose examination 4. patients with known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis 5. will be transferred to another hospital which is not the study site within 72 hours. 6. receipt of any experimental treatment for covid-19 within the 30 days prior to the time of the screening evaluation.